NCT04775680

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

A Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination With PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Adagene (Suzhou) Limited · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. The primary objective of Phase Ib: To evaluate the maximum tolerated dosage (MTD) of ADG106 in combination with PD-1 antibody in advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma, and to determine the recommended phase II clinical studies dosage (RP2D).

Conditions

• Solid Tumor
• Non Hodgkin Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	ADG106 injection	ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
BIOLOGICAL	PD-1 antibody injection	PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle

Timeline

• Start date: 2021-03-11
• Primary completion: 2023-02-09
• Completion: 2023-02-09
• First posted: 2021-03-01
• Last updated: 2023-04-24

Locations

1 site across 1 country: China